7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Eye Health

What an OCT Scan Shows in Macular Degeneration: Fluid, Drusen and the Case for Treatment

24 min read
What an OCT Scan Shows in Macular Degeneration: Fluid, Drusen and the Case for Treatment

Key Takeaways

  • An OCT scan images the retina in cross-section at a resolution of a few microns, fine enough to show fluid pockets before any blur is noticed.
  • Drusen appear on OCT as domes lifting the retinal pigment epithelium, and the NIH AREDS classification grades them as small, medium (63–124 microns) or large (125 microns or more).
  • Fluid within or beneath the retina on OCT is the defining sign of wet AMD and the usual trigger for an anti-VEGF treatment discussion; drusen alone usually mean monitoring.
  • Anti-VEGF injections block the protein that drives leaky vessel growth and are typically given monthly at first, with intervals then adjusted by the specialist based on each scan.
  • A dry macula on OCT after injections means wet AMD is inactive, not gone, because the abnormal vessels usually remain and can reactivate.
  • Geographic atrophy, the advanced dry form, shows on OCT as missing retinal layers with light passing through to the choroid, and it does not respond to anti-VEGF injections.
Quick Answer

An OCT scan in macular degeneration shows a cross-section of the macula so your eye doctor can see drusen (deposits under the retina that mark dry AMD), fluid pockets that signal wet AMD, and areas of thinning called atrophy. Fluid on the scan is the finding that usually prompts a discussion about anti-VEGF injections; drusen without fluid usually means monitoring instead.

You rest your chin on the plastic cradle, stare at a small green cross, and a faint line of light sweeps across your vision. Eight seconds, maybe ten. The technician says the doctor will go through the pictures with you, and you are left looking at a screen full of orange and yellow stripes that seem to mean something to everyone but you.

That image is an OCT scan, and for macular degeneration it has become the single most informative test an eye clinic owns. It cannot tell you how you feel about the words “age-related macular degeneration.” It can tell your doctor, in layers a few thousandths of a millimeter thick, whether the changes in your macula are the slow, deposit-forming kind or the leaking, treatable kind.

This explainer walks through what those stripes represent, how drusen and fluid look on the screen, why one finding leads to watchful monitoring and the other to a treatment conversation, and what to ask when the results land in front of you.

What does an OCT scan show, and why is it central to macular degeneration care?

OCT stands for optical coherence tomography: a non-contact imaging test that uses reflected light to build a cross-sectional picture of the retina, the light-sensing tissue at the back of the eye. If a standard retinal photograph is a satellite view of a landscape, OCT is the geologist’s cut through the cliff face, showing each layer in order.

The macula is the small central area of the retina that handles reading, faces and fine detail. Age-related macular degeneration, usually shortened to AMD, is a condition in which that area deteriorates with age. The National Eye Institute describes it as a leading cause of vision loss in people over 50, and it comes in two broad forms: a dry form marked by deposits and thinning, and a wet form marked by abnormal, leaking blood vessels.

What the scan shows, in practical terms, is three things an eye doctor needs to know:

  • Whether there are drusen, the deposits beneath the retina that define early and intermediate dry AMD, and how large they are.
  • Whether there is fluid within or beneath the retina, the hallmark of wet AMD and the finding that typically opens a discussion about treatment.
  • Whether parts of the retina have thinned or disappeared, the pattern called atrophy that marks advanced dry AMD.

The resolution is remarkable. A healthy central retina is only about a quarter of a millimeter thick, and OCT resolves structures within it at a scale of a few microns, a micron being one thousandth of a millimeter. That precision is why the scan can pick up a pocket of fluid before you notice any blur, and why repeated scans are used to judge whether a treatment is doing what it should.

How an OCT scan for macular degeneration actually works

The physics sounds complicated; the experience is not. You sit at a tabletop machine, rest your chin and forehead against supports, and look at a fixation target. A beam of low-power, near-infrared light scans across the macula. Each layer of the retina reflects that light slightly differently, and the instrument measures the tiny delays and intensities of those reflections, much as ultrasound measures echoes of sound. Software assembles thousands of these measurements into a cross-section, and then stacks many cross-sections into a three-dimensional map.

Ophthalmologist consulting elderly patient with OCT imaging equipment: How an OCT scan for macular degeneration actually wor

Nothing touches the eye, there is no radiation, and the light is not bright enough to be uncomfortable. Cleveland Clinic notes the scan itself takes only a few minutes, though your pupils may be dilated with drops first, which blurs near vision for a few hours and makes driving home inadvisable. Some clinics scan without dilation when the pupil is naturally wide enough.

The output comes in two main forms. The first is the cross-sectional slice, usually displayed in a color scale where strongly reflective tissue appears bright (red, yellow or white) and weakly reflective material appears dark (blue or black). Fluid, being clear, is dark. The second is a thickness map, a top-down view that color-codes how thick the retina is at each point, so swelling shows as a warm-colored island.

A newer variant, OCT angiography, uses the same light to detect the movement of blood cells and map retinal and choroidal blood vessels without injecting any dye. It can help confirm the abnormal vessel network of wet AMD, though many clinics still use dye-based fluorescein angiography when the picture is unclear. Whichever route is taken, the images are compared with any earlier scans, because change over time often matters more than a single snapshot.

What a healthy macula looks like on an OCT scan

Knowing the normal picture makes the abnormal one easier to read. On a healthy cross-section, the retina appears as a neatly layered band that dips in the center. That dip is the fovea, the pit where cone photoreceptors are packed most densely and where your sharpest vision lives.

Running along the bottom of the band is a bright, smooth line: the retinal pigment epithelium, or RPE, a single layer of cells that nourishes the photoreceptors above it and clears their waste. Beneath the RPE lies a thin membrane called Bruch’s membrane, and beneath that the choroid, a bed of blood vessels that supplies the outer retina with oxygen.

Just above the RPE sits another bright line that clinicians call the ellipsoid zone. It represents the light-sensing segments of the photoreceptors. When that line is intact and continuous, the cells that actually capture images are in good structural shape. When it is broken or faded, vision in that spot is often reduced even if the rest of the retina looks fine.

In a healthy eye, three things hold true on OCT:

  • The RPE line is smooth, with no bumps lifting it from Bruch’s membrane.
  • There are no dark pockets within or beneath the retina.
  • Layer thickness is even, and the foveal dip is symmetrical.

AMD disturbs each of these in a recognizable order. Drusen bump the RPE. Fluid creates dark spaces. Atrophy thins the layers until, in places, the RPE and photoreceptors vanish and light passes straight through to the choroid below. Learning to spot those three departures from normal is most of what reading an AMD scan involves.

Drusen on an OCT scan: the quiet signature of dry AMD

Drusen are yellowish deposits of fats and proteins that accumulate beneath the RPE, between it and Bruch’s membrane. On a retinal photograph they look like pale specks. On OCT they are far more informative: each druse appears as a small dome that lifts the bright RPE line away from the membrane beneath it, like a pebble under a sheet.

Ophthalmologist explaining OCT scan results to elderly patient: Drusen on an OCT scan: the quiet signature of dry AMD

Size matters, and OCT measures it. The NIH Age-Related Eye Disease Studies classification, which most clinicians use, divides drusen into small (under 63 microns), medium (63 to 124 microns) and large (125 microns or more). For scale, 125 microns is roughly the width of a retinal vein where it leaves the optic nerve, or a little wider than a human hair. A few small drusen are common with age and are not AMD. Medium drusen define early AMD; large drusen, or many medium ones, define intermediate AMD.

The scan also reveals a druse’s texture. Uniformly bright, dome-shaped drusen are the classic type. A different pattern, subretinal drusenoid deposits (sometimes called reticular pseudodrusen), sits above the RPE rather than below it and appears as a rippled layer. Clinicians pay attention to this pattern because it is associated with a higher likelihood of progression to late disease.

Here is the point most people find reassuring: drusen alone do not call for injections. There is no treatment that removes them, and some drusen flatten or fade on their own over the years. What drusen do is set the monitoring schedule. A person with large drusen will typically be asked to return for repeat scans more often than someone with a handful of small ones, and to use an Amsler grid at home, the square of lines that reveals distortion. The National Eye Institute’s AREDS2 research found that a specific antioxidant and zinc formulation lowered the risk of progression to advanced AMD by about 25 percent over five years in people with intermediate disease; whether that applies to you is a question for your eye doctor, not a shelf.

What fluid means: the OCT scan for wet AMD

Wet AMD begins when fragile new blood vessels grow from the choroid through Bruch’s membrane and into the space beneath the retina. Clinicians call this choroidal neovascularization, or more simply a membrane. These vessels leak plasma and sometimes blood, and that leakage is what OCT sees.

Fluid shows up as darkness, because clear liquid reflects almost no light. Three patterns matter:

  • Intraretinal fluid: dark, rounded cysts within the retinal layers, often giving the tissue a honeycomb look. This usually means the leak is affecting the retina directly.
  • Subretinal fluid: a dark, crescent-shaped space between the photoreceptors and the RPE, lifting the retina like a blister.
  • Pigment epithelial detachment: the RPE line itself is domed upward by fluid or by the vessel membrane beneath it, a taller and broader bump than any druse.

Alongside fluid, the scan may show the membrane itself as a disorganized bright mass under the retina, flecks of hyperreflective material (bright dots that may represent blood or inflammatory cells), and sometimes a dark layer that suggests bleeding.

Wet AMD accounts for a minority of all AMD, yet, according to Mayo Clinic and the NHS, it is responsible for most of the severe vision loss the condition causes, because fluid distorts and damages the photoreceptors quickly. That asymmetry is why fluid on an OCT carries so much weight. A dry macula with drusen is a reason to watch. A macula with new fluid is, in nearly every guideline, a reason to talk about treatment promptly.

Fluid can also tell the clinician how active the disease is during treatment. A scan that goes from honeycombed to flat after injections shows the leak is responding; a scan where fluid returns is a signal to adjust the plan. The images do the talking at every visit.

Dry vs wet AMD on OCT: a side-by-side view

Because the two forms of AMD overlap in symptoms yet diverge sharply in management, it helps to see how their OCT features line up. The table below summarizes what clinicians look for; your own scan may show elements of both, since wet AMD develops on a background of dry changes.

OCT feature Typical in dry AMD Typical in wet AMD What it usually means for care
Drusen (bumps under the RPE) Present; small to large Often present in the background Monitoring interval; discussion of risk reduction
Intraretinal or subretinal fluid (dark pockets) Absent Present, the defining finding Referral for treatment discussion
Pigment epithelial detachment Rare, small drusenoid domes Common, often with vessel membrane beneath Supports a wet AMD diagnosis
Hyperreflective material under retina Uncommon Common (vessel membrane, blood) May prompt angiography to confirm
Atrophy (thinning, missing layers) Defines advanced dry AMD (geographic atrophy) Can develop after long-standing disease or scarring No injections for atrophy itself; vision support
Typical next step Repeat scan on a schedule set by the clinician Prompt assessment for anti-VEGF therapy Decision rests with the treating team

Two caveats deserve space. First, a small amount of fluid can occasionally appear in dry AMD without any leaking vessels, for instance when drusen degenerate, and experienced readers distinguish this from true wet disease using the overall pattern and sometimes angiography. Second, the categories are not permanent. The NHS and Mayo Clinic both note that dry AMD can progress to wet AMD, which is precisely why people with intermediate dry disease are asked to keep their follow-up appointments and to report new distortion between them rather than waiting.

Who is usually offered an OCT scan for macular degeneration, and who is asked to wait

OCT is not a screening test for the general population. It is ordered when there is a reason to look closely at the macula, and the reasons cluster into a few groups.

People most likely to be scanned include anyone with new distortion or a central blur, anyone whose routine eye examination shows drusen or pigment changes, anyone already diagnosed with AMD in either eye, and anyone receiving injections for wet AMD, since each treatment visit normally begins with a scan. A strong family history of AMD or a known diagnosis in the other eye also lowers the threshold for imaging, because the NHS notes that the second eye is at higher risk once the first is affected.

Who is usually asked to wait? Mostly, people whose scans are reassuring. Small drusen without fluid, in a person with normal vision, typically leads to a routine recall rather than an urgent plan. The same is true for early AMD findings picked up incidentally. “Wait” here does not mean neglect; it means scheduled repeat scans, an Amsler grid at home, and attention to modifiable factors. Both the NHS and Mayo Clinic highlight smoking as the strongest controllable risk factor for progression, and they point to a diet rich in leafy greens and fish, blood pressure control and regular exercise as sensible measures, though the evidence for diet is observational rather than proof of cause.

There is also a treatment-side version of waiting. Someone with wet AMD whose scans have been dry for several visits may be moved to longer intervals between injections, a strategy sometimes called treat-and-extend. The decision to extend, shorten or pause is made by the retina specialist on the basis of what each OCT shows, and it is not a decision anyone should make for themselves by skipping an appointment.

How OCT findings build the case for treatment

Modern wet AMD treatment rests on a molecule called vascular endothelial growth factor, or VEGF, a signaling protein that tells blood vessels to grow and become leaky. Anti-VEGF medicines are antibodies or antibody fragments that bind VEGF and block it. They are given as an injection into the vitreous, the clear gel filling the eye, after the surface is numbed and cleaned with antiseptic. The injection itself takes seconds.

OCT is both the trigger and the referee for this therapy. The trigger: the presence of new intraretinal or subretinal fluid, together with signs of a vessel membrane, is what prompts a specialist to recommend starting. The referee: at each subsequent visit, the scan shows whether the fluid has cleared, persisted or returned, and the interval to the next injection is set accordingly. The NHS describes treatment as usually monthly to begin with, with the schedule then adjusted to the individual response.

What the evidence actually shows is worth stating plainly. Anti-VEGF injections, in the large trials summarized by the National Eye Institute and NHS, stabilized vision in most participants and improved it in a proportion; they do not restore a retina that has already scarred or atrophied, and they must usually be continued, often for years, to hold the vessels in check. They treat and control wet AMD; they do not remove it.

Risks are low but real, and clinicians review them before you consent: a sore, red or gritty eye for a day or two is common; serious infection inside the eye (endophthalmitis), retinal detachment and a rise in eye pressure are uncommon but need urgent attention. Which anti-VEGF agent is used, how often, and for how long are decisions for the prescribing specialist, who will weigh your scans, your other eye and your general health.

What the days and weeks after an OCT scan usually look like

The path after the scan depends almost entirely on what it showed, so it helps to sketch the two main routes.

If the scan shows drusen without fluid. Most people get their result the same day, often while looking at the image with the doctor. You will usually be given an Amsler grid, shown how to test one eye at a time, and told how to contact the clinic if the lines bend or a patch goes missing. A follow-up scan is booked at an interval chosen by the clinician based on drusen size and the other eye. Nothing else needs to happen in the days that follow, which can feel oddly anticlimactic after the anxiety of the appointment.

If the scan shows fluid. The timeline tightens. The NHS advises that wet AMD should be assessed and treated promptly, because untreated leakage can damage photoreceptors within weeks. You may have a dye-based or OCT angiography test to confirm the membrane, then a first injection, sometimes at the same visit. After an injection, Mayo Clinic describes a day or two of mild irritation, a red spot on the white of the eye where the needle entered, and occasionally floaters; you will be asked to keep the eye clean and report pain or worsening vision. The next visit, typically about four weeks later during the initial phase, starts with another OCT so the response can be seen before the next decision is made.

Over the following months, the scans become the diary of the disease. A clinician will compare today’s cross-section with last month’s, watching whether cysts shrink, whether the retina flattens, and whether the central thickness number falls. People often find it reassuring to ask to see the two images side by side, because the change is usually visible to an untrained eye once it has been pointed out.

Geographic atrophy and the other findings OCT can reveal

Not every important finding on an AMD scan is a druse or a pocket of fluid. Three others come up often enough to deserve plain explanation.

Geographic atrophy. This is the advanced form of dry AMD, in which patches of RPE and the photoreceptors above it waste away. On OCT the layered band thins and then simply stops; because the RPE is missing, light passes through to the choroid beneath, producing a telltale bright column under the gap. These patches tend to enlarge slowly over years and can merge. Anti-VEGF injections do not treat atrophy. Medicines that block part of the immune system’s complement pathway have been approved in some countries for geographic atrophy; what the trial evidence shows is a slowing of the growth of the atrophic area as measured on imaging, not an improvement in vision, and their place in care remains a matter for the retina specialist and local guidance.

Fibrosis. After long-standing wet AMD, the vessel membrane can turn into a scar, appearing on OCT as a dense, bright mass with the overlying layers disorganized. Scar tissue does not respond to injections, which is one reason prompt treatment of active fluid matters.

Look-alikes. OCT also helps rule out conditions that mimic AMD. Central serous chorioretinopathy produces subretinal fluid in younger people without drusen; diabetic macular edema produces cysts alongside the vessel changes of diabetes; an epiretinal membrane is a wrinkled sheet on the retinal surface that distorts vision without any leak. Each has a different plan, and the scan is usually what separates them.

The practical message is that “advanced AMD” is not one thing. Atrophy and active leakage can coexist in the same eye, and the care plan is built around whichever elements the scan shows.

OCT scan results explained: the terms you may hear in the consulting room

Retina clinics have a dialect, and much of it refers directly to the OCT image. These are the words most likely to come up, each in one sentence.

  • Hyperreflective and hyporeflective: bright and dark on the scan; fluid is hyporeflective, blood and scar are hyperreflective.
  • Central retinal thickness (CRT): the thickness of the retina at the fovea in microns, a number that rises with swelling and falls as fluid clears.
  • IRF and SRF: shorthand for intraretinal fluid and subretinal fluid, the two main fluid locations.
  • PED: pigment epithelial detachment, the RPE lifted by fluid or by a vessel membrane.
  • CNV or MNV: choroidal or macular neovascularization, the abnormal vessels of wet AMD.
  • Ellipsoid zone disruption: a break in the bright photoreceptor line, which often matches a spot of reduced vision.
  • Dry macula: a scan with no fluid, which in wet AMD means the disease is currently controlled, not gone.
  • Active versus inactive: whether the scan shows new or persistent fluid (active) or none (inactive).
  • Hypertransmission: the bright column beneath an area of atrophy where light passes through the missing RPE.

Two numbers are worth asking about at every visit. The first is central retinal thickness, because its trend over successive scans is one of the simplest measures of whether treatment is working. The second is the interval to your next appointment, because in treat-and-extend care that interval is itself the clinician’s summary of how stable the scan looks.

Finally, remember that the color scale varies between machines and clinics. A scan that looks alarmingly red on one display may be ordinary on another. What matters is the shape of the layers and the comparison with your earlier images, not the hue.

What people often get wrong about OCT and macular degeneration

Misunderstandings cluster around this test, partly because the images are so visually dramatic. These are the ones that cause the most unnecessary worry or the most dangerous complacency.

“My OCT was clear, so I don’t have AMD.” A normal scan is reassuring, but very early changes can be subtle, and OCT is read alongside a dilated examination and sometimes photographs. The diagnosis belongs to the whole assessment, not one image.

“Drusen means I’m going to go blind.” Most people with drusen never develop the wet form or significant atrophy. Mayo Clinic notes that dry AMD typically progresses slowly and that many people keep useful central vision for years; AMD does not cause total blindness, because peripheral vision is spared.

“Injections are a one-off fix.” Anti-VEGF treatment controls leakage while it is being given. The NHS describes it as ongoing, with intervals tailored to the scan, and stopping without the specialist’s agreement risks the fluid returning silently.

“Once treated, my wet AMD turned back into dry AMD.” A dry macula on OCT after injections means the leak is inactive. The abnormal vessels usually remain and can reactivate, which is why monitoring continues.

“Supplements can treat wet AMD.” The AREDS2 formulation studied by the National Eye Institute lowered the risk of progression in intermediate dry AMD; it is not a treatment for active leakage and does not replace injections.

“The scan hurts or involves radiation.” It involves neither. Nothing touches the eye and the light is low-power infrared.

“If my vision feels fine, I can skip the follow-up scan.” Fluid often appears on OCT before you notice any change, especially if your other eye is compensating. The scan exists precisely to catch what you cannot feel.

Questions to ask your care team about your OCT scan

Fifteen minutes in a consulting room goes quickly, and an image-heavy discussion is easy to nod through without absorbing. Writing questions down beforehand changes the conversation. These are the ones that tend to produce the most useful answers.

  • Which form of AMD does my scan show, dry or wet, and is it early, intermediate or advanced?
  • Can you show me the drusen, fluid or atrophy on the image, and compare it with my previous scan if there is one?
  • Is there any fluid at all, and if so, where: within the retina, beneath it, or under the RPE?
  • What is my central retinal thickness today, and which direction has it moved?
  • Does my other eye show any changes, and how does that affect my risk?
  • If you are recommending injections, what are you hoping the next scan will show, and how will you decide the interval?
  • If you are recommending monitoring, how often should I be scanned, and what should prompt me to come in earlier?
  • Would OCT angiography or dye angiography add anything to the picture in my case?
  • Are there risk-reduction steps you would suggest for me specifically, including whether the AREDS2-type formulation applies to my stage?
  • Who do I contact, and how quickly, if I notice new distortion or a dark patch between visits?

A small practical tip: ask whether the clinic can give you a printed or digital copy of your scan report. Having your own record of the central thickness numbers and the fluid status makes it far easier to follow the story across visits, and it is invaluable if you ever need to see a different clinician.

Most retina specialists welcome these questions. The scan is their main tool, and explaining it to you is part of using it well.

When to call your doctor: red-flag signs in macular degeneration

Macular degeneration rarely announces itself with pain, which is why the warning signs are visual and why they need to be acted on quickly rather than watched. Contact your eye clinic the same day, or seek urgent eye care, if you notice any of the following in either eye:

  • Straight lines that suddenly look bent, wavy or broken, especially on an Amsler grid or on door frames and text.
  • A new blurred, gray or dark patch in the center of your vision, or a sense that part of a face or word is missing.
  • A rapid drop in reading vision over days rather than months.
  • Colors looking faded or objects looking smaller in one eye compared with the other.

If you have recently had an eye injection, treat these as emergencies and call immediately:

  • Increasing pain, redness or light sensitivity in the injected eye in the days after treatment, which can signal infection inside the eye.
  • A sudden shower of new floaters, flashes of light, or a shadow or curtain spreading across your vision, which can signal retinal detachment.
  • Worsening vision rather than the expected gradual settling.

Keep testing each eye separately. Both the NHS and Mayo Clinic point out that the stronger eye masks changes in the weaker one, so a quick daily check with one eye covered is more useful than any amount of looking with both. Between visits, you are the monitoring system; the OCT confirms what you report.

Nothing in this article replaces that call. The scan findings, the interpretation and every decision about monitoring or treatment belong to your treating team, who have your images, your history and your other eye in front of them.

Frequently asked questions

What does an OCT scan show in macular degeneration?

It shows the layers of the macula in cross-section, revealing drusen (deposits beneath the retinal pigment epithelium), fluid within or under the retina, and areas of thinning called atrophy. Drusen indicate dry AMD and set the monitoring schedule; fluid indicates wet AMD and usually prompts a treatment discussion. The scan also measures central retinal thickness, a number clinicians track across visits to judge whether swelling is improving.

What do drusen on an OCT scan look like?

Drusen appear as small, rounded bumps that lift the bright line of the retinal pigment epithelium away from the membrane beneath it. Clinicians measure their height and width in microns and grade them as small, medium or large using the NIH AREDS classification. A few small drusen are a normal part of aging; medium or large drusen define early or intermediate dry AMD and usually lead to more frequent scans rather than treatment.

How is an OCT scan for wet AMD different from one for dry AMD?

The machine and the procedure are identical; the difference is in what the image shows. In wet AMD the scan reveals dark pockets of fluid within or beneath the retina, often with a dome-shaped detachment of the pigment epithelium and bright material from abnormal vessels. In dry AMD there is no fluid, only drusen and, in advanced disease, thinning. Fluid is what shifts the plan from watching to treating.

Does an OCT scan hurt, and does it use radiation?

No on both counts. The scan uses low-power near-infrared light, nothing touches the eye, and it takes only a few minutes. You may have dilating drops first, which blur near vision and cause light sensitivity for a few hours, so arrange a lift home. Some clinics can scan without dilation if your pupils are naturally wide enough. The main discomfort people report is holding still and staring at the fixation target.

Can an OCT scan tell if treatment is working?

Yes, that is one of its main roles. Each injection visit normally begins with a scan, and the clinician compares it with the previous one, looking for shrinking cysts, a flatter retina and a lower central thickness number. If fluid has cleared, the interval to the next injection may be lengthened; if fluid persists or returns, it may be shortened. The decision about timing rests with the retina specialist.

How often will I need an OCT scan if I have macular degeneration?

It depends on the stage and whether you are being treated. People with early dry changes are usually scanned at routine intervals set by their clinician; those with intermediate drusen are seen more often. During anti-VEGF treatment for wet AMD, a scan is typically done at every injection visit, which the NHS describes as monthly at first. Your care team sets the schedule based on what each scan shows.

What does "OCT scan results explained" mean when the report says my macula is dry?

A dry macula means the scan shows no fluid within or beneath the retina. If you have wet AMD and are being treated, it means the leak is currently inactive and controlled, not that the condition has gone, because the abnormal vessels usually remain. If you have dry AMD, it simply confirms that no wet changes have appeared. Either way, monitoring continues, and new distortion between visits should still be reported promptly.

Can fluid on OCT mean something other than wet AMD?

Yes. Subretinal fluid can occur in central serous chorioretinopathy, cysts can occur in diabetic macular edema or after other retinal problems, and occasionally small amounts of fluid appear in dry AMD when drusen break down. Experienced clinicians use the full pattern, your history and sometimes OCT angiography or dye angiography to tell these apart. This is why fluid on a scan leads to further assessment rather than an automatic injection.

Will an OCT scan show whether I need anti-VEGF injections?

It provides the key evidence. New or persistent fluid together with signs of a vessel membrane is what guidelines use to identify active wet AMD, the condition anti-VEGF injections are designed to treat. The scan does not make the decision by itself; the specialist weighs it alongside your vision, your other eye, any angiography and your overall health before recommending whether to start, continue or adjust treatment.

What is geographic atrophy on an OCT scan?

Geographic atrophy is the advanced form of dry AMD. On OCT it appears as areas where the retinal pigment epithelium and the photoreceptor layers are missing, so the band of tissue thins and light passes straight through to the choroid beneath, creating a bright column under the gap. These patches enlarge slowly over years. Anti-VEGF injections do not treat atrophy; management focuses on monitoring, risk reduction and low-vision support.

References

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.

Dr. Şule Eren
Dr. Şule Eren, MD
Author
View profile →
Published November 21, 2026
Keep Reading

More from the Blog

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.